Facile synthesis and antiproliferative activity of new 3-cyanopyridines

Hassan M. Abdel-aziz1, Sobhi M. Gomha2*, Abdelaziz A. El-Sayed3,4, Yahia Nasser Mabkhot5*, Abdulrhman Alsayar6 and Abdullatif Bin Muhsinah6

Abstract

Background: Pyridines have been reported to possess various pharmacological activities.

Results: Sodium 3-oxo-3-(2-oxo-2H-chromen-3-yl)prop-1-en-1-olate (2) and sodium 3-oxo-3-(3-oxo-3H-benzo[f]chromen-2-yl)prop-1-en-1-olate (7) were prepared and reacted with 2-cyano-N'-(1-aryl(heteryl)ethylidene)acetohydrazides 3a–d to produce 2-oxo-1,2-dihydropyridine-3-carbonitrile derivatives 5a–d and 9a–d, respectively, in good yields. Also, 3a–d reacted with sodium (2-oxocyclopentylidene)methanolate (11a) or sodium (2-oxocyclohexylidene)methanolate (11b) to yield 2-oxo-tetrahydro-1H-cyclopenta[b]pyridine-3-carbonitriles 13a–d and 2-oxo-hexahydropyridine-3-carbonitriles 13e–h, respectively. The mechanisms that account for the formation of the products are discussed. Additionally, the structures of all the newly synthesized products are confirmed, based on elemental analysis and spectral data. Several of the newly synthesized compounds are evaluated for their antitumor activity against HEPG2 and their structure activity relationship (SAR) was studied.

Conclusions: The results revealed that the pyridine derivatives 5c and 5d (IC50 = 1.46, 7.08 µM, respectively) have promising antitumor activity against liver carcinoma cell line (HEPG2), compared to the reference drug, doxorubicin.

Keywords: 2-Cyanoacetohydrazide, Cyclization, 3-Pyridinecarbonitriles, 3-Quinolinecarbonitriles, Antitumor activity

Introduction

The pyridine core is a key constituent in a scope of bioactive compounds which occur artificially and naturally. It has been appeared to have a wide scope of biological applications [1–3]. Among these, substituted cyano-pyridines were found to have antihypertensive [4], antipyretic, anti-inflammatory and analgesic properties [5]; cardiotonic [6], antimicrobial [7], and anticancer activities [8, 9]. Among the successful examples as drug candidates possessing the pyridine core are streptonigrone, lavendamycin and streptonigrin, which are depicted in the literature as anticancer agents. Some pyridine derivatives were contemplated for their topoisomerase inhibitory action and cytotoxicity against a few human malignant growth cell lines, thus marking them as novel anticancer agents [10]. Accordingly, it has been accounted those different pyridine derivatives, as bioisosteres of α-terthiophene (protein kinase C inhibitor) [11], have significant topoisomerase I and II inhibitory activity and cytotoxicity against many human cancer cell lines [12–15].

Early reports on the ability of α-terpyridine to form a metal complex [16] and to bind with DNA/RNA [17] have been the reason for the investigation of pyridine derivatives as antitumor agents. In light of the above discoveries and in continuation of our endeavors to synthesize new antitumor compounds [18–27], the aim of this report is to synthesize a new series of 3-pyridinecarbonitriles, which are anticipated to be active as antitumor agents.

© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Results and discussion

The synthetic strategies adopted for the synthesis of the intermediates and target compounds are depicted in Schemes 1, 2 and 3. In Schemes 1 and 2, sodium 3-oxo-3-(2-oxo-H-chromen-3-yl)prop-1-en-1-olate (2) and sodium 3-oxo-3-(3-oxo-3H-benzof[2]chromen-2-yl)prop-1-en-1-olate (7) were prepared from a reaction of the respective 2-acetyl-3H-benzof[2]chromen-3-one (1) or 2-acetyl-3H-benzof[2]chromen-3-one (6) with ethyl formate in dry ether containing sodium methoxide, according to reported methods [28]. The structures of 2 and 7 were confirmed by chemical transformations.

The treatment of sodium salt 2 or 7 with the appropriate 2-cyano-N'-1-aryl(heteryl) ethyldiene)aceto- hydrizides 3a–d [29–31] in acetic acid containing piperidine acetate afforded products 5a–d and 9a–d, respectively, in good yields (Schemes 1 and 2).

The structures of the reaction products 5a–d and 9a–d were established and confirmed by their elemental analysis and spectral data (MS, IR, 1HNMR, 13CNMR). Thus, the structure of 5a is supported by its mass spectrum, which showed a molecular ion corresponding to the formula C23H15N3O3 (M+, 381). The 1H-NMR spectrum showed characteristic signals at δ 7.24–7.18 (m, 9H, Ar–H), 7.96 (d, 1H, J = 4.8 Hz, pyridine-H5), 8.33 (d, 1H, J = 4.8 Hz, pyridine-H4), 9.22 (s, 1H, Coumarin-H4) ppm. Its IR spectrum showed the characteristic bands at ν = 2226 (CN), 1725, 1673 (2C=O) cm⁻¹.

To account for the formation of the products 5a–d and 9a–d, it is suggested that the studied reactions started with a nucleophilic attack by the methylene group of compound 3 at the formyl group of compound 2 or 7, which formed in situ due to the reaction of the formyl salts with water. This resulted in the formation of the non-isolable intermediate 4 or 8, followed by cyclization through the elimination of the water molecule, leading to the formation of the final pyridine derivatives 5 or 9 (Schemes 1 and 2).

Similarly, the 2-cyano-N-(1-substituted ethyldiene) acetohydrazides 3a–d reacted with the appropriate sodium (2-oxocyclopentylidene)methanolate (11a) [32] or sodium 2-oxocyclohexylidene)methanolate (11b) [32] in acetic acid containing piperidine acetate to give 2-oxo-1-((1-aryl(heteryl)ethyldiene)amino)-1H-cycloalkan[b]pyridine-3-carbonitrile derivatives 13a–h, respectively (Scheme 3). The structure of 13a–d has been assigned as a reaction product on the basis of analytical and spectral data. The IR spectrum displayed absorption bands at 2227 cm⁻¹ due to C≡N function, at 1670 cm⁻¹ due to amide C=O function. The 1H-NMR spectrum (DMSO-d₆) exhibited one singlet signal at δ = 2.41 ppm assignable to methyl protons, multiplet signals at δ = 1.27–1.85 (m, 8H, 4CH₂), 2.18–2.26 (m, 1H, CH), 2.41 (s, 3H, CH₃), 3.42 (m, 1H, CH), 3.75 (m, 1H, CH), in addition to a multiplet signal at δ 7.24–7.75 ppm, due to aromatic protons. The mass spectrum showed a molecular ion peak at m/z = 281, corresponding to the molecular formula C₁₇H₁₉N₅O₆.

As depicted in Scheme 3, the formation of 10 seems to start with an initial attack by a carbanion of the active methylene compound 3 to the formyl group of the salt 11, which formed in situ due to the reaction of the formyl salts 11 with water, forming. Subsequent enolization followed by elimination of water led to product 13.

Antitumor activity

The antitumor activity of compounds 5a–d, 9a–d and 13a–d was determined against a liver carcinoma cell line, HEPG2. Doxorubicin was utilized as a reference drug and showed IC₅₀ = 0.72 μM against this liver carcinoma cell line. Collected data were used to plot a dose–response curve, of which the concentration (μM) of the tested compounds required to kill of 50% of the cell population (IC₅₀) was recorded in DMSO–D₆ on a Bruker DRX NMR spectrometer operating at 400 MHz for 1H and 100 MHz for 13C NMR. Chemical shift (δ) values are expressed in ppm and are referenced to the residual solvent signals of DMSO-d₆.

The outcomes showed that the vast majority of the tested compounds demonstrated extraordinary variable activity contrasted with the reference drug, as shown in Table 1 and Fig. 1. The descending order of activity of the new compounds was as follows: 5c > 5d > 5a > 13c > 5b > 9a > 9b > 9d > 13d > 13a > 13b.

Examination of the SAR leads to the following conclusions.

The pyridine derivatives 5c and 5d (IC₅₀ = 1.46, 7.08 μM, respectively) demonstrated potent antitumor activity against HEPG2, while pyridines 5a, 9c, 13c, 5b, 9a, showed moderate activity (IC₅₀ = 22.3–42.8 μM). The remaining pyridines showed poor antitumor activity against this liver carcinoma cell line (IC₅₀ > 65 μM).

The pyridine derivatives having coumarine ring 5a–d exhibited more anticancer activity than pyridines having naphtho coumarine ring 9a–d while the latter pyridines 9a–d exhibited more activity than cyclopenta[b]pyridines 13a–d.

Experimental section

Melting points were recorded in open capillaries using an electrothermal Gallenkamp apparatus and are uncorrected. Elemental analyses were carried out by the microanalytical center at Cairo University. The 1H and 13C NMR spectra were recorded in DMSO-d₆ on a Bruker DRX NMR spectrometer operating at 400 MHz for 1H and 100 MHz for 13C NMR. Chemical shift (δ) values are expressed in ppm and are referenced to the residual solvent signals of DMSO-d₆.
The mass spectra were recorded on GCMSQ1000-EX Shimadzu spectrometers. The IR spectra were measured on a Pye-Unicam SP300 instrument.

**Synthesis of the sodium salt of 3-(3-hydroxyprop-2-enoyl)-2H-chromen-2-one (4) and the sodium salt of 2-(3-hydroxyprop-2-enoyl)-3H-benzo[f]chromen-3-one (7)**

Sodium methoxide (0.054 g, 10 mmol) and ether (20 mL) were poured through a separating funnel to a three-necked flask (250 mL), then the appropriate 3-acetyl-2H-chromen-2-one (1) or 2-acetyl-3H-benzo[f]chromen-3-one (6) (10 mmol of each) and ethyl formate (0.74 g, 10 mmol) were added and stirred. The formed solid products 4 and 7 were collected via filtration and used directly in the following reactions.

**Synthesis of 2-oxo-1,2-dihydropyridine-3-carbonitrile derivatives 5a–d and 9a–d**

An aqueous solution of 4 or 7 (10 mmol of each), the appropriate cyanoacetic acid hydrazones 3a–d (10 mmol) and piperidine acetate (1 mL) was refluxed for 10 min, then acetic acid (1.5 mL) was added to the hot solution.
The formed product was separated and recrystallized from the suitable solvent to yield products 5a–d or 9a–d. The analytical data of the obtained products 5a–d and 9a–d are listed below:

**2-Oxo-6-(2-oxo-2H-chromen-3-yl)-1-((1-phenylethylidene) amino)-1,2-dihydropyridine-3-carbonitrile (5a)**

Yield 81%; yellow solid; mp 182–184°C (EtOH); IR (KBr): ν 3038, 2926 (C–H), 2226 (CN), 1725, 1673 (2C=O), 1603 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ 2.41 (s, 3H, CH₃), 7.02–7.88 (m, 9H, Ar–H), 7.96 (d, 1H, J=4.8 Hz, pyridine-H5), 8.33 (d, 1H, J=4.8 Hz, pyridine-H4), 9.22 (s, 1H, Coumarin-H4) ppm; ¹³C NMR (DMSO-d₆): δ 18.3 (CH₃), 96.7, 116.3, 118.5, 120.3, 123.6, 126.2, 127.6, 127.9, 128.4, 129.0, 129.6, 132.6, 134.3, 134.8, 142.5, 147.1, 156.4, 158.0 (Ar–C), 162.4, 163.1 (2C=O) ppm; MS m/z (%): 381 (M⁺, 25), 352 (69), 203 (81), 104 (85), 64 (100). Anal. Calcd for C₂₃H₁₅N₃O₃ (381.38): C, 72.43; H, 3.96; N, 11.02. Found C, 72.31; H, 3.89; N, 10.96.

**2-Oxo-6-(3-oxo-3H-benzo[f] chromen-2-yl)-1-((1-phenylethylidene) amino)-1,2-dihydropyridine-3-carbonitrile (5b)**

Yield 83%; yellow solid; mp 206–208°C (EtOH); IR (KBr): ν 3027, 2929 (C–H), 2227 (CN), 1727, 1673 (2C=O), 1601 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ 2.31 (s, 3H,
CH$_3$), 2.42 (s, 3H, CH$_3$), 7.13–7.80 (m, 8H, Ar–H), 7.90 (d, 1H, $J$=4.8 Hz, pyridine-H5), 8.26 (d, 1H, $J$=4.8 Hz, pyridine-H4), 9.12 (s, 1H, Coumarin-H4) ppm; $^{13}$C NMR (DMSO-$d_6$): δ 18.0, 22.4 (CH$_3$), 94.7, 117.5, 119.3, 120.2, 121.9, 124.8, 125.0, 127.3, 127.7, 128.8, 129.1, 130.2, 132.6, 133.8, 140.2, 149.2, 155.1, 157.9 (Ar–C), 162.0, 164.2 (2C=O) ppm; MS m/z (%): 395 (M$^+$, 18), 315 (37), 203 (58), 91 (80), 64 (100). Anal. Calcd for C$_{24}$H$_{17}$N$_3$O$_3$ (395.41): C, 72.90; H, 4.33; N, 10.63. Found C, 72.98; H, 4.27; N, 10.51.

Scheme 3 Synthesis of pyridine-3-carbonitriles 13a-h

| 13 | X     | R             | 13 | X     | R             |
|----|-------|---------------|----|-------|---------------|
| a  | CH$_2$| C$_6$H$_5$    | e  | CH$_3$CH$_2$ | C$_6$H$_5$    |
| b  | CH$_2$| 4-CH$_3$C$_6$H$_4$ | f  | CH$_3$CH$_2$ | 4-CH$_3$C$_6$H$_4$ |
| c  | CH$_2$| | g  | CH$_3$CH$_2$ | |
| d  | CH$_2$| 7-oxocoumarin | h  | CH$_3$CH$_2$ | 7-oxocoumarin |
2-Oxo-6-(2-oxo-2H-chromen-3-yl)-1-[(1-3-oxo-3H-benzo[f]chromen-2-yl)ethylidene]amino]-1,2-dihydropyridine-3-carbonitrile (5c)

Yield 80%; yellow solid; mp 244–246 °C (DMF); IR (KBr): ν 3047, 2936 (C–H), 2221 (CN), 1723, 1670 (C=O), 1602 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ 2.40 (s, 3H, CH₃), 7.16–7.81 (m, 10H, Ar–H), 7.96 (d, 1H, J = 4.8 Hz, pyridine-H5), 8.26 (d, 1H, J = 4.8 Hz, pyridine-H4), 8.93 (s, 1H, Naphthoquinone-H4), 9.25 (s, 1H, Coumarin-H4) ppm; MS m/z (%): 449 (M⁺, 14), 382 (39), 218 (100), 173 (70), 91 (67), 64 (58). Anal. Calcd for C₃₀H₁₇N₃O₅ (499.47): C, 72.14; H, 3.43; N, 8.41. Found C, 72.03; H, 3.26; N, 8.28.

2-Oxo-6-(3-oxo-3H-benzo[f]chromen-2-yl)-1-[(1-phenylethylidene)amino]-1,2-dihydropyridine-3-carbonitrile (9a)

Yield 77%; yellow solid; mp 206–208 °C (DMF); IR (KBr): ν 3051, 2929 (C–H), 2226 (CN), 1723, 1670 (C=O), 1602 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ 2.40 (s, 3H, CH₃), 7.25–7.81 (m, 11H, Ar–H), 7.96 (d, 1H, J = 4.8 Hz, pyridine-H5), 8.28 (d, 1H, J = 4.8 Hz, pyridine-H4), 8.93 (s, 1H, Naphthoquinone-H4) ppm; ¹³C NMR (DMSO-d₆): δ 18.8 (CH₃), 95.8, 103.7, 116.7, 119.5, 121.0, 122.7, 123.7, 126.1, 127.2, 127.7, 128.0, 129.1, 130.4, 131.4, 132.6, 134.0, 134.5, 145.9, 155.3, 157.6 (Ar–C), 162.1, 164.3 (C=O) ppm; MS m/z (%): 431 (M⁺, 36), 306 (58), 218 (36), 139 (42), 91 (77), 64 (100). Anal. Calcd for C₂₂H₁₇N₃O₅ (431.44): C, 75.16; H, 3.97; N, 9.74. Found C, 75.03; H, 3.91; N, 9.59.

2-Oxo-6-(3-oxo-3H-benzo[f]chromen-2-yl)-1-[(1-(p-tolyl)ethylidene)amino]-1,2-dihydropyridine-3-carbonitrile (9b)

Yield 82%; yellow solid; mp 222–224 °C (DMF); IR (KBr): ν 3047, 2935 (C–H), 2221 (CN), 1733, 1682 (C=O), 1601 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ 2.30 (s, 3H, CH₃), 2.43 (s, 3H, CH₃), 7.17–7.81 (m, 10H, Ar–H), 7.95 (d, 1H, J = 4.8 Hz, pyridine-H5), 8.41 (d, 1H, J = 4.8 Hz, pyridine-H4), 8.94 (s, 1H, Naphthoquinone-H4) ppm; ¹³C NMR (DMSO-d₆): δ 18.4, 22.7 (CH₃), 94.7, 105.9, 117.0, 120.4, 120.9, 121.4, 122.0, 124.8, 126.3, 127.0, 128.7, 128.6, 129.8, 131.4, 131.8, 133.6, 135.3, 136.0, 142.6, 151.4, 155.3 (Ar–C), 163.6, 165.1 ppm; MS m/z (%): 445 (M⁺, 100), 341 (36), 265 (54), 182 (74), 64 (83). Anal. Calcd for C₂₂H₁₇N₃O₅ (445.47): C, 75.49; H, 4.30; N, 9.43. Found C, 75.32; H, 4.16; N, 9.27.

2-Oxo-1-[(1-(2-oxo-2H-chromen-3-yl)ethylidene)amino]-6-(3-oxo-3H-benzo[f]chromen-2-yl)ethylenemino]-1,2-dihydropyridine-3-carbonitrile (9c)

Yield 80%; brown solid; mp 231–233 °C (DMF); IR (KBr): ν 3040, 2961 (C–H), 2223 (CN), 1739, 1726, 1675 (C=O), 1597 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ

---

**Table 1 Cytotoxic activities of tested compounds against liver carcinoma cell line (HEPG2)**

| Compd no. | R       | R'      | IC₅₀ (µM) |
|-----------|---------|---------|----------|
| Doxorubicin | –       | –       | 0.72     |
| 5a        | C₆H₅    | –       | 223      |
| 5b        | 4-MeC₆H₄ | –       | 40.9     |
| 5c        | –       | –       | 1.46     |
| 5d        | –       | –       | 7.08     |
| 9a        | C₆H₅    | –       | 42.8     |
| 9b        | 4-MeC₆H₄ | –       | 65.3     |
| 9c        | –       | –       | 23.9     |
| 9d        | –       | –       | 66.5     |
| 13a       | C₆H₅    | –       | 74.3     |
| 13b       | 4-MeC₆H₄ | –       | 92.5     |
| 13c       | –       | –       | 39.0     |
| 13d       | –       | –       | 72.4     |

The most active compounds are in italic.
2.41 (s, 3H, CH$_3$), 7.27–7.93 (m, 10H, Ar–H), 8.03 (d, 1H, \( J = 4.8 \) Hz, pyridine-H5), 8.38 (d, 1H, \( J = 4.8 \) Hz, pyridine-H4), 8.97 (s, 1H, Naphthocoumarin-H4), 9.13 (s, 1H, Coumarin-H4) ppm; MS \( m/z \) (%): 499 (M$^+$, 36), 360 (51), 218 (100), 154 (73), 104 (55), 64 (81). Anal. Calcd for C$_{30}$H$_{17}$N$_3$O$_5$ (499.47): C, 72.14; H, 3.43; N, 8.41. Found C, 72.01; H, 3.25; N, 8.27.

2-Oxo-6-(3-oxo-3H-benzo[f]chromen-2-yl)-1-((1-3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)amino)-1,2-dihydropyridine-3-carbonitrile (9d)

Yield 76%; brown solid; mp 271–273 °C (DMF); IR (KBr): \( \nu \) 3042, 2938 (C–H), 2229 (CN), 1736, 1729, 1676 (3C=O), 1607 (C=N) cm$^{-1}$; 1H NMR (DMSO-$d_6$): $\delta$ 2.44 (s, 3H, CH$_3$), 7.41–7.95 (m, 12H, Ar–H), 8.12 (d, 1H, \( J = 4.8 \) Hz, pyridine-H5), 8.46 (d, 1H, \( J = 4.8 \) Hz, pyridine-H4), 8.89, 8.93 (2 s, 2H, 2Naphthocoumarin-H4) ppm; MS \( m/z \) (%): 549 (M$^+$, 22), 315 (62), 288 (67), 154 (100), 91 (38), 64 (77). Anal. Calcd for C$_{34}$H$_{19}$N$_3$O$_5$ (549.53): C, 74.31; H, 3.48; N, 7.65. Found C, 74.18; H, 3.29; N, 7.44.

Synthesis of sodium salt of cycloalkanones 11a, b

In a three-necked flask (250 mL), sodium methoxide (0.054 g, 10 mmol) and ether (20 mL) were poured through a separating funnel, the appropriate cyclopentanone (10a) or cyclohexanone (10b) (10 mmol of each) with ethyl formate (0.74 g, 10 mmol) were added, and then stirred. The formed solid products 11a and 11b were collected and used directly in the following reactions.

2-Oxo-6-(3-oxo-3H-benzo[f]chromen-2-yl)-1-((1-phenylethylidene)amino)-1,2-dihydropyridine-3-carbonitrile derivatives 13a–h

A solution of 11a or 11b (10 mmol of each), the appropriate cyanoacid hydrazones 3a–d (10 mmol) and piperidine acetate (1 mL) in water (3 mL) was refluxed for 10 min. Acetic acid (1.5 mL) was added to the hot solution. The solid product was filtered off and recrystallized from the proper solvent to give products 13a–h. The physical constants and spectral data of the obtained products 13a–h are listed below:

2-Oxo-1-((1-phenylethylidene)amino)octahydro-1H-cyclopenta[b]pyridine-3-carbonitrile (13a)

Yield 73%; yellow solid; mp 204–206 °C (EtOH); IR (KBr): \( \nu \) 3033, 2925 (C–H), 2227 (CN), 1670 (C=O), 1607 (C=N) cm$^{-1}$; 1H NMR (DMSO-$d_6$): \( \delta \) 2.44 (s, 2H, 2Naphthocoumarin-H4) ppm; MS \( m/z \) (%): 281 (M$^+$, 16), 203 (40), 127 (100), 79 (38), 64 (77). Anal. Calcd for C$_{17}$H$_{19}$N$_3$O (281.35): C, 72.57; H, 6.81; N, 14.94. Found C, 72.42; H, 6.69; N, 14.70.

2-Oxo-1-((1-p-tolyl)ethylidene)amino)octahydro-1H-cyclopenta[b]pyridine-3-carbonitrile (13b)

Yield 75%; yellow solid; mp 193–195 °C (EtOH); IR (KBr): \( \nu \) 3027, 2948 (C–H), 2221 (CN), 1675 (C=O), 1602 (C=N) cm$^{-1}$; 1H NMR (DMSO-$d_6$): \( \delta \) 1.23–1.85 (m, 8H, 4CH$_2$), 2.18–2.26 (m, 6H, 3CH$_2$, 2CH$_3$), 3.42 (m, 1H, CH), 3.75 (m, 1H, CH$_3$), 7.24–7.75 (m, 5H, ArH) ppm; 13C NMR (DMSO-$d_6$): \( \delta \) 23.7, 25.3, 28.5, 33.4, 34.9, 36.3, 41.1, 62.0, 95.8, 125.3, 126.2, 129.1, 134.4, 160.3, 171.6 ppm; MS \( m/z \) (%): 281 (M$^+$, 16), 203 (40), 127 (100), 91 (48), 64 (52). Anal. Calcd for C$_{17}$H$_{19}$N$_3$O (281.35): C, 72.57; H, 6.81; N, 14.94. Found C, 72.42; H, 6.69; N, 14.70.
2-Oxo-1-((1-(2-oxo-2H-chromen-3-yl)ethylidene)amino)octahydro-1H-cyclopenta[b]pyridine-3-carbonitrile (13c)

Yield 77%; brown solid; mp 204–206 °C (EtOH); IR (KBr): ν 3033, 2928 (C–H), 1668 (2C=O), 1597 (C=O) cm⁻¹; ¹H NMR (DMSO-d₆): 6 δ 1.32–1.90 (m, 8H, 4CH₂), 2.13–2.19 (m, 1H, CH), 2.41 (s, 3H, CH₃), 3.48 (m, 1H, CH), 3.73 (m, 1H, CH), 7.36–7.88 (m, 5H, ArH) ppm; MS m/z (%): 399 (M⁺, 12), 291 (60), 183 (80), 91 (49), 64 (100).

Anal. Calcd for C₂₅H₂₃N₃O₃ (413.47): C, 72.62; H, 5.61; N, 10.16. Found C, 72.16; H, 5.30; N, 10.52. Found C, 72.03; H, 5.19; N, 10.33.

2-Oxo-1-((1-phenylethylidene)amino)decahydroquinoline-3-carbonitrile (13e)

Yield 73%; yellow solid; mp 204–206 °C (EtOH); IR (KBr): ν 3033, 2928 (C–H), 2227 (CN), 1670 (C=O), 1607 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): 6 δ 1.18–1.96 (m, 10H, 5CH₂), 2.04–2.09 (m, 1H, CH), 2.42 (s, 3H, CH₃), 3.49 (m, 1H, CH), 3.68 (m, 1H, CH), 7.28–7.80 (m, 5H, ArH) ppm; MS m/z (%): 295 (M⁺, 100), 239 (43), 160 (73), 91 (63), 64 (48).

Anal. Calcd for C₁₉H₂₁N₃O₃ (363.41): C, 73.76; H, 7.40; N, 13.42.

Evaluation of the antitumor activity using Viability assay

The cytotoxic evaluation of the synthesized compounds was carried out at the Regional Center for Mycology and Biotechnology at Al-Azhar University, Cairo, Egypt, according to a reported method [33].

Materials and methods

Chemicals

All chemicals used in this study are of high analytical grade. They were obtained from (either Sigma-Alderich or Biorad).

Human tumor cell lines

The tumour cell lines were obtained frozen in liquid nitrogen (−180 °C) from the American Type Culture Collection (ATCC® HB-8065™) and was maintained at the National Cancer Institute, Cairo, Egypt, by serial sub-culturing.

Measurement of potential cytotoxic activity

The cytotoxic activity was measured in vitro on human cancer cell line (HEPG2) using Sulforhodamine-B stain (SRB) assay.
Cells were plated in 96 multi well plates for 24 h before treatment with the compounds to allow attachment of the cells to the wall of the plate.

- Different concentrations of the compound under test (0, 6.25, 12.5, 25, 50 and 100 µg/mL) were added to the cell monolayer. Triplicate wells were prepared for each individual dose.
- Monolayer cells were incubated with the compounds for 48 h at 37 °C and in atmosphere of 5% CO₂.
- After 48 h cell was fixed, washed and stained with Sulforhodamine B stain.

- The relation between surviving fraction and drug concentration was plotted and IC₅₀ (the concentration required for 50% inhibition of cell viability) was calculated for each compound by Sigma-plot software.

Conclusions

The results of the present study indicate that the cyanoacid hydrazones and sodium 3-oxo-3-heteroarylprop-1-en-1-olates or sodium (2-oxocycloalkylidene)methanolates are useful precursors for the synthesis of various functionalized 3-pyridinecarbonitriles. In addition, they indicate that these reactions are region-specific, as in each case, one product of good yield was produced. Most of the synthesized compounds were evaluated for their anti-cancer activity against the liver carcinoma cell lines. Also, their structure activity relationship (SAR) was studied. The results revealed that the pyridine derivatives 5c and 5d (IC₅₀ = 1.46, 7.08 µM, respectively) have promising antitumor activity against liver carcinoma cell line (HEPG2). The prepared compounds are expected to be of pharmacological interest.

Abbreviations

TLC: thin layer chromatography; HepG2: liver carcinoma cell line; EtOH: ethanol; DMF: dimethylformamide; m.p.: melting point; IR: infra-red; ATCC: American Type Culture Collection; SAR: structure activity relationship.

Authors’ contributions

SMG and YNM designed research; HMA and AA performed research; AAE performed the biological activities studies. ABM analyzed the data; HMA, SMG and YNM wrote the final manuscript. All authors read and approved the final manuscript.

Funding

The financial support by the Deanship of Scientific Research (prolific research group No R.G.P.2/23/41) King Khalid University, Saudi Arabia.

Availability of data and materials

The datasets and samples of the compounds used during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Chemistry Department, Faculty of Science, University of Bani Suef, Bani Suef, Egypt. 2 Chemistry Department, Faculty of Science, University of Cairo, Giza 12613, Egypt. 3 Chemistry Department, Faculty of Science, Islamic University in Almadinah Almonawara, Almadinah Almonawara 42351, Saudi Arabia.

4 Zoology Department, Faculty of Science, Zagazig University, Zagazig, Egypt.

5 Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia. 6 Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

Received: 27 August 2019 Accepted: 7 December 2019
Published online: 28 December 2019

References

1. Ranu BC, Jana R, Sowmiah S (2007) An improved procedure for the three-component synthesis of highly substituted pyridines using ionic liquid. J Org Chem 72:3152–3154

2. Abbas IM, Gomha SM, Elaesser MM, Bauomi MA (2015) Synthesis and biological evaluation of new pyridines containing imidazole moiety as antimicrobial and anticancer agents. Turk J Chem 39:334–346

3. Abdelrazek FM, Gomha SM, Shabban MEB, Rabee KA, El-Shermy HN, Abdallah AM, Metz P (2019) One-pot three-component synthesis and molecular docking of some novel 2-thiazolylpyridines as potent antimicrobial agents. Mini Rev Med Chem 19:527–538

4. Baldwin JJ, Engelhardt EL, Hirschmann R, Ponticello GS, Atkinson JG, Washe BK, Sweet CS, Scriabine A (1980) Heterocyclic analogues of the anti-hypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine. J Med Chem 23:65–70

5. Manna F, Chimenti F, Bolasco A, Filippelli A, Palla A, Mercantini R (1992) Anti-inflammatory, analgesic and antipyretic 4,6-disubstituted 3-cyanopyridine-2-ones and 3-cyano-2-aminopyridines. Eur J Med Chem 27:627–632

6. Belkht AA, Baraka AM (2005) Novel milrinone analogs of pyridine-3-carbonitrile derivatives as promising cardiotonic agents. Eur J Med Chem 40:1405–1413

7. Abdel-Azzam AAM, El-Subbagh HL, Kunieda T (2005) Lewis acid-promoted transformation of 2-alkoxy pyridines into 2-aminopyridines and their anti-bacterial activity. Part 2: remarkably facile C–N bond formation. Bioorg Med Chem 13:4929–4935

8. El-Sayed HA, Moustafa AH, Haikal AEFZ, Abu-El-Halawa R, El Ashry ESH (2011) Synthesis, antitumor and antimicrobial activities of 4-(4-chlorophenyl)-3-cyano-2-[(β-O-glycosyloxy)-6-(thien-2-yl)-nicotinonitrile. Eur J Med Chem 46:2948–2954

9. Malik A, Mohsen M, Aziz H, Rizk O, Shabban O, El-Sayed M, Sherif ZA, Ashour H (2016) New 3-Cyano-2-substituted pyridines induce apoptosis in MCF 7 breast cancer cells. Molecules 21:230

10. Thapa P, Karki R, Choi HY, Choi JH, Yun M, Jeong BS, Jung MJ, Nam JM, Na Y, Cho WJ, Kwon Y, Lee E-S (2010) Synthesis of 2-thienyl-2-y1 or -3-y1-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure–activity relationship. Bioorg Med Chem 18:2245–2254

11. Xu WC, Zhou Q, Ashendel CL, Chang CT, Chang CJ (1999) Novel protein kinase C inhibitors: synthesis and PKC inhibition of β-substituted polythiopeptide derivatives. Bioorg Med Chem Lett 9:2279–2282

12. Zhao LX, Moon YS, Basnet A, Kim EK, Jahng Y, Park JG, Jeong TC, Cho WJ, Choi SU, Lee CO, Lee SY, Lee CS, Lee ES (2004) The discovery and synthesis of novel adenosine receptor (Aₐ₉) antagonists. Bioorg Med Chem Lett 14:1333–1336

13. Zhao LX, Shrench J, Park JK, Jahng Y, Jeong BS, Jeong TC, Lee CS, Lee ES (2008) Synthesis, cytotoxicity and structure–activity relationship study of pyridines. Arch Pharm 291:1091–1095

14. Son JK, Zhao LX, Basnet A, Thapa P, Karki R, Na Y, Jahng Y, Jeong TC, Jeong BS, Lee CS, Lee ES (2008) Synthesis of 2,6-dialkyl-substituted pyridines and their antitumor activities. Eur J Med Chem 43:675–682

15. Jeong BS, Choi HY, Thapa P, Karki R, Lee E, Nam JM, Na Y, Ha E-M, Kwon Y, Lee ES (2011) Synthesis, Topoisomerase I and II Inhibitory activity, cytotoxicity, and structure–activity relationship study of rigid analogues
16. Eryazici I, Moorefield CN, Newkome GR (2008) Square-planar Pd(II), Pt(II), and Au(III) terpyridine complexes: their syntheses, physical properties, supramolecular constructs, and biomedical activities. Chem Rev 108:1834–1895

17. Patel KK, Plummer EA, Darwish M, Rodger A, Hannon MJ (2008) Aryl substituted ruthenium bis-terpyridine complexes: intercalation and groove binding with DNA. J Inorg Biochem 91:220–229

18. Gomha SM, Salah TA, Abdelhamid AO (2015) Synthesis, characterization and pharmacological evaluation of some novel thiazole and thiadiazole incorporating pyrazole moiety as potent anticancer agents. Monatsh Chem 146:149–158

19. Gomha SM, Abdel-aziz HM (2015) Synthesis and antitumor activity of 1,3,4-thiadiazole derivatives bearing coumarin ring. Heterocycles 91:583–592

20. Dawood KM, Gomha SM (2015) Synthesis and anti-cancer activity of 1,3,4-thiadiazole and 1,3-thiazole derivatives having 1,3,4-oxadiazole moiety. J Heterocycl Chem 52:1400–1405

21. Abbas IM, Gomha SM, Elneairy MAA, Elaasser MM, Mabrouk BKA (2015) Antimicrobial and anticancer evaluation of novel synthetic tetracyclic system through Dimroth rearrangement. J Serb Chem Soc 80:1251–1264

22. Gomha SM, Abbas IM, Elneairy MAA, Elaasser MM, Mabrouk BKA (2015) Synthesis and biological evaluation of novel fused triazolo[4,3-a]pyrimidines. Turk J Chem 39:510–531

23. Gomha SM, Zaki YH, Abdelhamid AO (2015) Utility of 3-acetyl-6-bromo-2H-chromen-2-one for synthesis of new heterocycles as potential anticancer agents. Molecules 20:21826–21839

24. Gomha SM, Riyadh SM, Mahmoud EA, Elaasser MM (2015) Chitosan-grafted-poly(4-vinylpyridine) as a novel copolymer basic catalyst for synthesis of arylazothiazoles and 1,3,4-thiadiazoles under microwave irradiation. Chem Heterocycl Comp 51:1030–1038

25. Gomha SM, Salah TA, Hassanean HME, Abdel-aziz H, Khedr MA (2016) Synthesis, characterization and molecular docking of novel bioactive thiadiazole-thiazole derivatives as promising cytotoxic antitumor drug. Molecules 21:1–17

26. Gomha SM, Badrey MG, Edrees MM (2016) Heterocyclization of a bis-thiosemicarbazone of 2,5-diacetyl-3,4-disubstituted-thiophene bis-thiosemicarbazones leading to bis-thiazoles and bis-1,3,4-thiadiazoles as anti-breast cancer agents. J Chem Res 40:120–125

27. Gomha SM, Abdallah MA, Mourad MA, Elaasser MM (2016) Application of Mannich and Michael reactions in synthesis of pyridopyrimido[2,1-b][1,3,5]thiadiazinones and pyridopyrimido[2,1-b][1,3]thiazinones and their biological activity. Heterocycles 92:688–699

28. Zelenin KN, Olenik SV, AlekseevVV, Potekhin AA (2001) Structure of cyanoacetylhydrazones of aldehydes and ketones. Russ J General Chem 71:1116–1120

29. Gomha SM, Khalil KD (2012) A Convenient ultrasound-promoted synthesis and cytotoxic activity of some new thiazole derivatives bearing a coumarin nucleus. Molecules 17:9335–9347

30. Refat HM, Fadda AA (2013) Synthesis and antimicrobial activity of some novel hydrazide, benzochromenone, dihydropyridine, pyrrole, thiazole and thiophene derivatives. Eur J Med Chem 70:419–426

31. Gomha SM, Abdallah MA (2013) An efficient synthesis of functionalized 2-(heteroaryly)-3H-benzof]chromen-3-ones and antibacterial evaluation. J Chem Res 5:298–303

32. Ahmed SA, Ahmed OM, Abdelhamid AO (2014) Synthesis and anti-tumor activities of new [1,2,4]triazolo[1,5-alpyrimidines. Eur J Chem 5:334–338

33. Gomha SM, Riyadh SM, Mahmoud EA, Elaasser MM (2015) Synthesis and anticancer activities of thiazoles, 1,3-thiazines, and thiazolidine using chitosan-grafted-poly(4-vinylpyridine) as basic catalyst. Heterocycles 91:1227–1243

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.